Halozyme Therapeutics opens European headquarters
Halozyme, a U.S. biotechnology company developing novel oncology and drug-delivery therapies, has established their European headquarters office in Basel, Switzerland.
“We evaluated several locations to set up our first European foothold and decided on Basel due to its outstanding biotechnology talent pool,” commented Laurie Stelzer, chief financial officer. “In Basel we found the right conditions – a top-notch life sciences talent pool, an overall attractive business environment and well-equipped lab space at the Technologie Park Basel.”
Basel, Switzerland is uniquely positioned as a life sciences location for companies along the entire value chain – from research to production and commercial stages. The location offers direct connections to the European market with its EuroAirport, state-of-the-art laboratory and manufacturing sites, and topped off with a 30’000 people-strong local life sciences workforce.
BaselArea.swiss is very pleased about Halozyme’s decision and welcomes the company to the local business community. The San Diego-based company is the latest of U.S. biotech companies to set up a European or global hub in the Basel region. Notable newcomers of 2016/17 are Ultragenyx, Roivant Sciences, W2O and Singulex.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More